What is the recommended dosage of Silymarin for liver health?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Silymarin Dosage for Liver Health

For general liver health support, silymarin 420 mg/day (divided doses) is the standard regimen, though clinical evidence does not support its use as a primary treatment for chronic liver diseases. 1

Standard Dosing Recommendations

General Liver Support

  • Standard dose: 420 mg/day divided into multiple doses (typically 140 mg three times daily or 210 mg twice daily) 1, 2
  • Commercial preparations typically contain 70-80% silymarin as the active ingredient 1, 3
  • Duration of treatment varies but studies have used 12-48 weeks for chronic conditions 4, 5

High-Dose Regimens (Specific Conditions)

  • High-dose: 1,050 mg/day (350 mg three times daily) has shown superior biochemical improvements in decompensated cirrhosis compared to standard dosing 4
  • Acute mushroom poisoning: 30-40 mg/kg/day administered for 3-4 days, typically given intravenously 1, 3
  • High-dose silymarin (700 mg three times daily) has been studied in NASH trials 5

Evidence-Based Efficacy by Condition

Limited or No Proven Benefit

  • The American Association for the Study of Liver Diseases states that clinical evidence does not currently support milk thistle for treatment of chronic liver diseases 1
  • Patients should not delay or replace conventional medical treatment with silymarin 1
  • In NASH, silymarin 700 mg three times daily did not significantly reduce NAFLD activity scores compared to placebo 5

Potential Benefits (Requires Confirmation)

  • Liver enzyme reduction: Silymarin significantly reduced ALT and AST levels, particularly in HBV and NAFLD patients 6
  • Fibrosis reduction: In NASH patients, 22.4% on silymarin had histologic fibrosis reduction (≥1 point) versus 6.0% on placebo (p=0.023) 5
  • Decompensated cirrhosis: High-dose silymarin (1,050 mg/day) improved Child-Pugh scores and quality of life 4
  • Alcoholic liver disease: Pooled data showed improved histology and prothrombin time, with reduced liver-related mortality (OR 0.54, p<0.01) 2

Critical Caveats

Regulatory and Quality Issues

  • Herbal supplements are not FDA-regulated with the same rigor as prescription medications 1
  • Silymarin concentrations vary considerably between manufacturers and preparations 1, 3
  • Always verify the actual silymarin content when calculating doses 3

Safety Profile

  • Generally well-tolerated with rare gastrointestinal disturbances and allergic skin rashes 2
  • No serious adverse events reported in major trials 4, 5

Monitoring Requirements

  • Patients with liver disease taking silymarin must continue regular monitoring as directed by their healthcare provider 1
  • Do not use silymarin as a substitute for evidence-based treatments like antivirals for hepatitis or lifestyle modification for NAFLD 1

Practical Algorithm for Dosing

For patients requesting silymarin despite limited evidence:

  1. Start with standard dose of 420 mg/day (140 mg three times daily with meals) 2, 6
  2. Consider high-dose regimen (1,050 mg/day) only in decompensated cirrhosis under close supervision 4
  3. Verify product contains 70-80% silymarin and calculate actual dose accordingly 1, 3
  4. Continue for minimum 12 weeks before assessing biochemical response 4, 6
  5. Monitor liver enzymes every 4-6 weeks 6

The only established indication is as an antidote for Amanita mushroom poisoning (30-40 mg/kg/day for 3-4 days), which requires immediate emergency medical treatment 1, 3

References

Guideline

Milk Thistle Counseling Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Silymarin Syrup Dosage and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

High Dose of Silymarin in Patients with Decompensated Liver Disease: A Randomized Controlled Trial.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2017

Research

A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.